DAWN Key Statistics, Chart & Performance
The current stock price of DAWN is 11.16 USD. In the past month the price increased by 19.74%. In the past year, price decreased by -9.78%.
DAWN Technical Analysis
ChartMill assigns a technical rating of 9 / 10 to DAWN. When comparing the yearly performance of all stocks, DAWN is one of the better performing stocks in the market, outperforming 81.79% of all stocks.
DAWN Fundamental Analysis
ChartMill assigns a fundamental rating of 4 / 10 to DAWN. While DAWN has a great health rating, there are worries on its profitability.
DAWN Financial Highlights
Over the last trailing twelve months DAWN reported a non-GAAP Earnings per Share(EPS) of -1.47. The EPS increased by 17.42% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -29.54% | ||
| ROE | -33.66% | ||
| Debt/Equity | 0 |
DAWN Forecast & Estimates
15 analysts have analysed DAWN and the average price target is 24.03 USD. This implies a price increase of 115.29% is expected in the next year compared to the current price of 11.16.
For the next year, analysts expect an EPS growth of 42.41% and a revenue growth 23.72% for DAWN
DAWN Ownership
DAWN Latest News, Press Relases and Analysis
About DAWN
Company Profile
Day One Biopharmaceuticals, Inc. operates as a holding company. The company is headquartered in Brisbane California, California and currently employs 184 full-time employees. The company went IPO on 2021-05-27. The company partners with clinical oncologists, families, and scientists to identify, acquire, and develop cancer treatments. Its commercial product, OJEMDA (tovorafenib), is an oral, brain-penetrant, selective type II rapidly accelerated fibrosarcoma (RAF) kinase inhibitor. OJEMDA is used for the treatment of patients over six months of age and older with relapsed or refractory pLGG harboring a BRAF fusion or rearrangement, or BRAF V600 mutation. Its pipeline product candidates include DAY301 and Emi-Le (emiltatug ledadotin). DAY301 is a novel Antibody Drug Conjugate, or ADC, targeting protein-tyrosine kinase 7, or PTK7. Emi-Le (emiltatug ledadotin) is a novel antibody drug conjugate (ADC) targeting the B7-H4 protein in clinical development to treat the rare cancer adenoid cystic carcinoma (ACC).
Company Info
DAY ONE BIOPHARMACEUTICALS I
1800 Sierra Point Parkway, Suite 200
Brisbane California CALIFORNIA US
CEO: Jeremy Bender
Employees: 184
Phone: 16504840899
DAY ONE BIOPHARMACEUTICALS I / DAWN FAQ
Can you describe the business of DAY ONE BIOPHARMACEUTICALS I?
Day One Biopharmaceuticals, Inc. operates as a holding company. The company is headquartered in Brisbane California, California and currently employs 184 full-time employees. The company went IPO on 2021-05-27. The company partners with clinical oncologists, families, and scientists to identify, acquire, and develop cancer treatments. Its commercial product, OJEMDA (tovorafenib), is an oral, brain-penetrant, selective type II rapidly accelerated fibrosarcoma (RAF) kinase inhibitor. OJEMDA is used for the treatment of patients over six months of age and older with relapsed or refractory pLGG harboring a BRAF fusion or rearrangement, or BRAF V600 mutation. Its pipeline product candidates include DAY301 and Emi-Le (emiltatug ledadotin). DAY301 is a novel Antibody Drug Conjugate, or ADC, targeting protein-tyrosine kinase 7, or PTK7. Emi-Le (emiltatug ledadotin) is a novel antibody drug conjugate (ADC) targeting the B7-H4 protein in clinical development to treat the rare cancer adenoid cystic carcinoma (ACC).
What is the current price of DAWN stock?
The current stock price of DAWN is 11.16 USD.
Does DAWN stock pay dividends?
DAWN does not pay a dividend.
What is the ChartMill rating of DAY ONE BIOPHARMACEUTICALS I stock?
DAWN has a ChartMill Technical rating of 9 out of 10 and a ChartMill Fundamental rating of 4 out of 10.
Can you provide the growth outlook for DAY ONE BIOPHARMACEUTICALS I?
The Revenue of DAY ONE BIOPHARMACEUTICALS I (DAWN) is expected to grow by 23.72% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
What is the employee count for DAWN stock?
DAY ONE BIOPHARMACEUTICALS I (DAWN) currently has 184 employees.
What is the Short Interest ratio of DAY ONE BIOPHARMACEUTICALS I (DAWN) stock?
The outstanding short interest for DAY ONE BIOPHARMACEUTICALS I (DAWN) is 13.33% of its float.